Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region

Shahrzad Salmasi, Kah Seng Lee, Long Chiau Ming, Chin Fen Neoh, Mahmoud E. Elrggal, Zaheer-Ud-Din Babar, Tahir Mehmood Khan, Muhammad Abdul Hadi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions. Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties including one from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in this study. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similar pharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. A structured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel®. Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1%) and nine (34.6%) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eight drug presentations (30.7%) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit price of $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price; low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on their income level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs): US$1150.63; and high income countries (HICs): US$1148.19. Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respective regions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countries and develop policies to ensure accessibility and affordability of anti-cancer drugs.

Original languageEnglish
Article number903
Number of pages11
JournalBMC Cancer
Volume17
DOIs
Publication statusPublished - 28 Dec 2017

Fingerprint

Mediterranean Region
Costs and Cost Analysis
Pharmaceutical Preparations
Neoplasms
Far East
Parity
Oman
Administrative Personnel
Taiwan
Health Care Costs

Cite this

Salmasi, Shahrzad ; Lee, Kah Seng ; Ming, Long Chiau ; Neoh, Chin Fen ; Elrggal, Mahmoud E. ; Babar, Zaheer-Ud-Din ; Khan, Tahir Mehmood ; Hadi, Muhammad Abdul. / Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region. In: BMC Cancer. 2017 ; Vol. 17.
@article{4ce2dfae38964ccbaed605bcdbc97a88,
title = "Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region",
abstract = "Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions. Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties including one from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in this study. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similar pharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. A structured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel{\circledR}. Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1{\%}) and nine (34.6{\%}) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eight drug presentations (30.7{\%}) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit price of $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price; low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on their income level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs): US$1150.63; and high income countries (HICs): US$1148.19. Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respective regions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countries and develop policies to ensure accessibility and affordability of anti-cancer drugs.",
keywords = "Anti-cancer drugs, Eastern Mediterranean, Pricing, South-East Asia, Western Pacific",
author = "Shahrzad Salmasi and Lee, {Kah Seng} and Ming, {Long Chiau} and Neoh, {Chin Fen} and Elrggal, {Mahmoud E.} and Zaheer-Ud-Din Babar and Khan, {Tahir Mehmood} and Hadi, {Muhammad Abdul}",
year = "2017",
month = "12",
day = "28",
doi = "10.1186/s12885-017-3888-y",
language = "English",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region. / Salmasi, Shahrzad; Lee, Kah Seng; Ming, Long Chiau; Neoh, Chin Fen; Elrggal, Mahmoud E.; Babar, Zaheer-Ud-Din; Khan, Tahir Mehmood; Hadi, Muhammad Abdul.

In: BMC Cancer, Vol. 17, 903, 28.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region

AU - Salmasi, Shahrzad

AU - Lee, Kah Seng

AU - Ming, Long Chiau

AU - Neoh, Chin Fen

AU - Elrggal, Mahmoud E.

AU - Babar, Zaheer-Ud-Din

AU - Khan, Tahir Mehmood

AU - Hadi, Muhammad Abdul

PY - 2017/12/28

Y1 - 2017/12/28

N2 - Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions. Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties including one from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in this study. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similar pharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. A structured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel®. Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1%) and nine (34.6%) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eight drug presentations (30.7%) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit price of $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price; low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on their income level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs): US$1150.63; and high income countries (HICs): US$1148.19. Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respective regions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countries and develop policies to ensure accessibility and affordability of anti-cancer drugs.

AB - Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions. Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties including one from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in this study. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similar pharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. A structured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel®. Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1%) and nine (34.6%) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eight drug presentations (30.7%) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit price of $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price; low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on their income level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs): US$1150.63; and high income countries (HICs): US$1148.19. Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respective regions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countries and develop policies to ensure accessibility and affordability of anti-cancer drugs.

KW - Anti-cancer drugs

KW - Eastern Mediterranean

KW - Pricing

KW - South-East Asia

KW - Western Pacific

UR - http://www.scopus.com/inward/record.url?scp=85039843421&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3888-y

DO - 10.1186/s12885-017-3888-y

M3 - Article

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 903

ER -